Neosporin expands with lip care line
NEW YORK Neosporin, a Johnson & Johnson Consumer Cos. brand, is diving into the dry lip segment with the launch of its new Neosporin Lip Health daily hydration therapy and Neosporin Lip Health overnight renewal therapy.
The new products, which are shipping now, will join a portfolio of existing Neosporin products, including Neosporin LT Lip Treatment for the treatment of cold sores and severely dry chapped lips.
The new lip products are clinically shown to restore visibly healthier lips in three days, according to the company.
Neosporin Lip Health daily hydration therapy contains SPF 20 to protect lips from sunburn and both formulas feature a patented combination of lipids and antioxidants to soften and smooth lips. Peptides, vitamins and emollients also help to nourish and strengthen lips over time.
Both products have a suggested retail price of $4.99.
McNeil Consumer Healthcare expands Visine line
MORRIS PLAINS, N.J. McNeil Consumer Healthcare on Wednesday announced the introduction of Visine Totality Multi-Symptom Relief — a new eye drop formulated to relieve the seven symptoms associated with eye irritation, including red, burning, watery, itchy, gritty, dry and irritated eyes.
The company also introduced Ultra-soft Visine Total Eye Soothing Wipes for cleansing the area around the eyes, removing make-up, debris and irritants like dust and pollen. The ophthalmologist- and dermatologist- tested wipes feature a blend of eight moisturizers, a cooling agent, and a gentle cleanser (Coco-Glucoside) derived from coconut and fruit sugars to sweep away debris. Safe for sensitive eyes and contact lens wearers, the wipes gently glide around the eyes to soothe the area and deliver clean, fresh, makeup-free eyes.
NAD questions dietary supplement’s safety; submits concerns to FTC, FDA
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Wednesday referred advertising from Metabolic Research around its Stemulite dietary supplement to the Federal Trade Commission and Food and Drug Administration for further review, following the company’s decision not to participate in an NAD review of advertising for the product.
As a part of its ongoing monitoring program and in conjunction with an initiative with the Council for Responsible Nutrition to expand the review of advertising claims for dietary supplements, NAD – the advertising industry’s self-regulatory forum – requested that the company provide supporting evidence for advertising claims including,“People who take Stemulite experience deep REM sleep, increased muscle gain and endurance, increased weight loss and fat loss and increased wellness and energy.”
As part of its review, NAD also expressed concerned about several testimonials on the Stemulite Web site.
The advertiser contacted NAD, and despite requesting and being given an extension of time within which to file its response, failed to do so. The advertiser represented to NAD that it would be conducting a study in the future and would participate after the completion of the study.
NAD noted that it is a well-settled principle of advertising law that an advertiser must possess adequate substantiation before it publishes advertising claims. NAD’s procedures provide that if an advertiser does not participate in the process, NAD may refer the advertising at issue to the appropriate government agency for further review.
NAD was “disappointed that the advertiser did not participate in the NAD inquiry, particularly in light of the health and weight-loss claims being made.” Based on the advertiser’s failure to participate, NAD will refer this matter to the FTC and FDA for possible law enforcement action.